The company intends to use the capital to fuel its ongoing pipeline development, with an additional provision granting underwriters a 30-day window to purchase up to $45 million in supplementary shares. While the stock has enjoyed a 22% gain year-to-date, this sudden injection of new equity into the market triggered an immediate cooling effect among shareholders.
In section Market Quotes
Dyne Therapeutics Shares Slip on $300 Million Offering
Investors reacted sharply to the news of a $300 million common stock offering from Dyne Therapeutics, sending shares tumbling 10% to $21.41 in after-hours trading Tuesday. The move marks a pivot for the clinical-stage biotech firm, which had seen its market valuation more than double over the past year.
A syndicate of financial institutions is managing the sale, with Morgan Stanley, Jefferies, and Evercore ISI serving as joint book-running managers alongside LifeSci Capital and Raymond James. Jones is acting as the lead manager for the transaction, which represents a significant capitalization effort for the firm.
Comments (0)
No comments yet. Be the first!